These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36789682)

  • 1. Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
    Napoli R; Berra C; Catarig AM; Di Loreto C; Donatiello E; Berentzen TL; Pitocco D; Giorgino F
    Diabetes Obes Metab; 2023 Jun; 25(6):1658-1667. PubMed ID: 36789682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
    Mohammedi K; Belhatem N; Berentzen TL; Catarig AM; Potier L
    Diabetes Obes Metab; 2023 Jul; 25(7):1855-1864. PubMed ID: 36869853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
    Yale JF; Catarig AM; Grau K; Harris S; Klimek-Abercrombie A; Rabasa-Lhoret R; Reardon L; Woo V; Liutkus J
    Diabetes Obes Metab; 2021 Oct; 23(10):2269-2278. PubMed ID: 34142429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.
    Rudofsky G; Catarig AM; Favre L; Grau K; Häfliger S; Thomann R; Schultes B
    Diabetes Res Clin Pract; 2021 Aug; 178():108931. PubMed ID: 34217773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
    Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
    Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
    Saravanan P; Bell H; Braae UC; Collins E; Deinega A; Dhatariya K; Machell A; Trent A; Strzelecka A
    Adv Ther; 2024 Nov; 41(11):4266-4281. PubMed ID: 39316289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
    Rajamand Ekberg N; Bodholdt U; Catarig AM; Catrina SB; Grau K; Holmberg CN; Klanger B; Knudsen ST
    Prim Care Diabetes; 2021 Oct; 15(5):871-878. PubMed ID: 34183269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
    Jain AB; Reichert SM; Amadid H; Braae UC; Bradley RM; Kim JW; Soo V; Yale JF
    Diabetes Obes Metab; 2024 May; 26(5):1799-1807. PubMed ID: 38468125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
    Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study.
    Bellido V; Abreu Padín C; Catarig AM; Clark A; Barreto Pittol S; Delgado E
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.
    Menzen M; Berentzen TL; Catarig AM; Pieperhoff S; Simon J; Jacob S
    Exp Clin Endocrinol Diabetes; 2023 Apr; 131(4):205-215. PubMed ID: 36599459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.
    Milenkovikj T; Chekorova Mitreva B; Jovanovska Mishevska S; Bitoska-Mileva I; Ahmeti I;
    Diabetes Res Clin Pract; 2023 Dec; 206():111018. PubMed ID: 37972857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study.
    van Houtum W; Schrömbges P; Amadid H; van Bon AC; Braae UC; Hoogstraten C; Herrings H
    Diabetes Ther; 2024 Aug; 15(8):1749-1768. PubMed ID: 38861137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.
    Holmes P; Bell HE; Bozkurt K; Catarig AM; Clark A; Machell A; Sathyapalan T
    Diabetes Ther; 2021 Nov; 12(11):2891-2905. PubMed ID: 34562237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
    Ji L; Dong X; Li Y; Li Y; Lim S; Liu M; Ning Z; Rasmussen S; Skjøth TV; Yuan G; Eliaschewitz FG
    Diabetes Obes Metab; 2021 Feb; 23(2):404-414. PubMed ID: 33074557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
    Garcia de Lucas MD; Miramontes-González JP; Avilés-Bueno B; Jiménez-Millán AI; Rivas-Ruiz F; Pérez-Belmonte LM
    Front Endocrinol (Lausanne); 2022; 13():995646. PubMed ID: 36187123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7
    Pratley RE; Aroda VR; Catarig AM; Lingvay I; Lüdemann J; Yildirim E; Viljoen A
    BMJ Open; 2020 Nov; 10(11):e037883. PubMed ID: 33199417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
    Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
    Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice.
    Catrina SB; Amadid H; Braae UC; Dereke J; Ekberg NR; Klanger B; Jansson S
    Diabetes Ther; 2024 Sep; 15(9):2079-2095. PubMed ID: 39052163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.